共 58 条
[1]
Huggins C(1941)Studies on prostatic cancer Arch Surg 43 209-642
[2]
Cornford P(2017)EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer Eur Urol 71 630-1038
[3]
Bellmunt J(2015)Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) Eur Urol 67 1028-746
[4]
Bolla M(2015)Chemohormonal therapy in metastatic hormone-sensitive prostate cancer N Engl J Med 373 737-1177
[5]
James ND(2016)Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Lancet 387 1163-677
[6]
Spears MR(2017)Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer N Engl J Med 32 671-3982
[7]
Clarke NW(2017)Abiraterone for prostate cancer not previously treated with hormone therapy N Engl J Med 20 3972-6403
[8]
Sweeney CJ(2014)Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer J Clin Oncol 13 6396-169
[9]
Chen Y-H(2017)Which factors predict overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post-docetaxel? Clin Genitourin Cancer 169 164-204
[10]
Carducci M(2002)Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 68 196-E73